Omnicell Inc.
OMCL | NASDAQ
$32.88
+$0.45 (+1.39%)
Sep 22, 2026, 11:36 AM ET · Market open
Company Profile
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
Key Executives
| Name | Position |
|---|---|
| Randall A. Lipps | Founder, Executive Chairman & CEO |
| Dave Ford | Senior Vice President & Chief People Officer |
| H. Baird Radford | Executive Vice President & Chief Financial Officer |
| Perry A. Genova | Senior Vice President & Chief Technology Officer |
| Stella Prefach | Senior VP & Chief Marketing Officer |
| Brian H. Nutt | Vice President, Chief Accounting Officer & Corporate Controller |
| Corey J. Manley | Executive Vice President, Chief Legal & Administrative Officer and Corporate Secretary |
| David J. Vanella | Senior Vice President of Quality & Product Regulatory |
| David Unger | Vice President of Investor Relations |
| Nnamdi Njoku | President & COO |
| Sara Dalmasso | Senior Vice President & GM of International |
| Tomer Stavitsky | Senior VP & Chief Corporate Development Officer |
| Vicki MacDevitt | Chief of Staff |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 18, 2026 | 4 | Filing |
| Aug 18, 2026 | 4 | Filing |
| Aug 18, 2026 | 4 | Filing |
| Aug 18, 2026 | 4 | Filing |
| Aug 10, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 05, 2026 | 10-Q | Quarterly Report |
| Jul 30, 2026 | 8-K | Current Report |
| Jul 17, 2026 | 4 | Filing |
| Jul 07, 2026 | S-8 | Filing |
| Jul 06, 2026 | 4 | Filing |
Omnicell Inc.
| Country | United States |
| IPO Date | Aug 6, 2001 |
| Industry | Medical - Healthcare Information Services |
| Sector | Healthcare |
| Employees | 3,485 |
| CEO | Randall A. Lipps |
Contact Details
4220 North Freeway Fort Worth,
Texas 76137 United States
Stock Details
| Ticker Symbol | OMCL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000926326 |
| CUSIP Number | 68213N109 |
| ISIN Number | US68213N1090 |
| SIC Code | 3571 |
Recent News
- 6 days ago / zacks.comHere's Why Omnicell (OMCL) is a Strong Value Stock
- 19 days ago / prnewswire.comTraceLink and Omnicell Integrate DSCSA Compliance Solution into Hospital Pharmacy Operations
- 22 days ago / businesswire.comOmnicell to Present at the Wells Fargo 21st Annual Healthcare Conference
- 29 days ago / zacks.comWhy Omnicell (OMCL) is a Top Value Stock for the Long-Term
- 1 month ago / fool.comOmnicell President Sells 6,753 Shares
- 1 month ago / zacks.comOmnicell Raises 2026 EPS Outlook as Memory Costs Pressure Margins
- 1 month ago / zacks.comOMCL Falls 20.1% in a Month as Booking and Margin Risks Build
- 2 months ago / gurufocus.comIs Omnicell Inc (OMCL) a Bargain After 4.7% Drop? GF Value Says Undervalued
- 2 months ago / zacks.comOMCL Q2 Earnings Call Highlights Titan XT Pipeline Growth
- 2 months ago / marketbeat.comOmnicell Q2 Earnings Call Highlights
Add to Watchlist
Select watchlists to add or remove OMCL